New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
1. Myriad Genetics published a meta-analysis showing GeneSight test efficacy. 2. Patients using GeneSight are 41% more likely to achieve remission. 3. 30% increase in response rates for patients using the GeneSight test. 4. Meta-analysis adds confidence in GeneSight's clinical utility for treating MDD. 5. Data will be submitted to payers to enhance patient access.